News
Executive Changes Hit NuVasive Hard
Advances in medical science have had a dramatic impact on the quality of care that patients receive. In the area of spinal surgery, NuVasive (NASDAQ: NUVA) has made a lot of headway with its minimally
Cerner Corporation Meets Expectations in Second Quarter With Solid Recurring Revenue
Cerner Corporation (NASDAQ: CERN) got off to a solid start in 2017 with its first-quarter results. The healthcare technology giant posted both revenue and earnings at the upper end of its guidance.On
Cerner Corporation Meets Expectations in Second Quarter With Solid Recurring Revenue
Cerner Corporation (NASDAQ: CERN) got off to a solid start in 2017 with its first-quarter results. The healthcare technology giant posted both revenue and earnings at the upper end of its guidance.On
Mighty AstraZeneca Takes a Lickin' on Failed Mystic Trial
When AstraZeneca (NYSE: AZN) spurned overtures from Pfizer (NYSE: PFE) to combine in one of the biggest merger deals of all time, it told investors not to worry. It had plenty of irons in the fire
Mighty AstraZeneca Takes a Lickin' on Failed Mystic Trial
When AstraZeneca (NYSE: AZN) spurned overtures from Pfizer (NYSE: PFE) to combine in one of the biggest merger deals of all time, it told investors not to worry. It had plenty of irons in the fire
Why Tetraphase Pharmaceuticals Fell 11.7% Today
After reporting positive trial results for its lead product candidate on July 25, Tetraphase Pharmaceuticals (NASDAQ: TTPH) announced a $60 million share offering today that will dilute investors, and
Baxter International Inc.'s Revenue Growth Snoozes, but Check Out the Earnings Growth
Baxter (NYSE: BAX) kept with its trend in the second quarter of marginal revenue growth, but included a substantial improvement in spending, resulting in an increase in earnings that once again beat
Natus Medical Inc Looks to Turn Things Around
Natus Medical (NASDAQ: BABY) continued the trend from the first quarter of the year: Revenue came in substantially higher in the second quarter, due to the addition of revenue from the company's
Did the Checkpoint Inhibitor Bubble Just Burst?
Shares of Agenus (NASDAQ: AGEN), a small-cap cancer immunotherapy company, were down by almost 16% at 1:20 p.m. Thursday as a result of AstraZeneca's (NYSE: AZN) Mystic trial missing its primary
Did the Checkpoint Inhibitor Bubble Just Burst?
Shares of Agenus (NASDAQ: AGEN), a small-cap cancer immunotherapy company, were down by almost 16% at 1:20 p.m. Thursday as a result of AstraZeneca's (NYSE: AZN) Mystic trial missing its primary
Novavax, Inc.: Buy the Dip?
Novavax's (NASDAQ: NVAX) investors can't seem to catch a break. The clinical-stage vaccine maker has been down on its luck ever since it released disappointing phase 3 trial results last year for its
Corning Exceeds Expectations on Optical and Gorilla Glass Strength
Corning Incorporated (NYSE: GLW) announced second-quarter 2017 results on Wednesday morning, easily beating expectations on both the top and bottom lines, thanks to strong showings from both its
Corning Exceeds Expectations on Optical and Gorilla Glass Strength
Corning Incorporated (NYSE: GLW) announced second-quarter 2017 results on Wednesday morning, easily beating expectations on both the top and bottom lines, thanks to strong showings from both its
Exact Sciences Continues to Surprise to the Upside
Exact Sciences (NASDAQ: EXAS) reported second-quarter financial results today that exceeded industry-watchers' forecasts, continuing a string of successes that has frustrated short-sellers and caused
Gilead Sciences Has 3 Available Options, but Only 1 Makes Sense
Gilead Sciences (NASDAQ: GILD) is nearing a crossroads of sorts. In short, AbbVie's (NYSE: ABBV) eight-week pan-genotypic hepatitis C combo of glecaprevir and pibrentasvir could emerge as a
Gilead Sciences Has 3 Available Options, but Only 1 Makes Sense
Gilead Sciences (NASDAQ: GILD) is nearing a crossroads of sorts. In short, AbbVie's (NYSE: ABBV) eight-week pan-genotypic hepatitis C combo of glecaprevir and pibrentasvir could emerge as a
Gilead Sciences, Inc. Boosts Its Full-Year Outlook Thanks to Stronger-Than-Expected Hep C Sales
When Gilead Sciences, Inc. (NASDAQ: GILD) reported its first-quarter results earlier this year, everyone expected sales for the biotech's hepatitis C franchise to be way down. Those expectations were
Gilead Sciences, Inc. Boosts Its Full-Year Outlook Thanks to Stronger-Than-Expected Hep C Sales
When Gilead Sciences, Inc. (NASDAQ: GILD) reported its first-quarter results earlier this year, everyone expected sales for the biotech's hepatitis C franchise to be way down. Those expectations were
Gilead Sciences, Inc. Boosts Its Full-Year Outlook Thanks to Stronger-Than-Expected Hep C Sales
When Gilead Sciences, Inc. (NASDAQ: GILD) reported its first-quarter results earlier this year, everyone expected sales for the biotech's hepatitis C franchise to be way down. Those expectations were
Biogen Inc Wants to Be the "Fastest-Growing Large-Cap Biotech Company"
Biogen (NASDAQ: BIIB) started the biotech earnings season off with a bang, generating enough revenue for the company to have confidence to increase its revenue guidance for the year. Earnings weren't
The CEO Behind Lipitor Is Working on a Promising New Cholesterol Drug
Lipitor is one of the most commonly prescribed medicines on the planet, and one of the men behind it, Roger Newton, is currently working on a cheap and effective cholesterol-lowering drug.In this
Why Amedisys Is Crashing 14.3% Today
After the Centers for Medicare and Medicaid Services (CMS) said it may reduce reimbursement for home healthcare by 0.4% in 2018, shares in Amedisys Inc. (NASDAQ: AMED) are losing 14.3% of their value
BASTIDE : FINALISATION DE 5 ACQUISITIONS EN FRANCE ACCROISSEMENT DES PARTS DE MARCHE EN RESPIRATOIRE ET DEVELOPPEMENT DE LA VENTE EN LIGNE
Le Groupe Bastide Le Confort Médical annonce avoir finalisé 5 opérations de croissance externe en juillet en France, quatre dans le domaine des prestations de services en Assistance....
Here's Why Tetraphase Pharmaceuticals Rose as Much as 26.8% Today
Shares of clinical-stage biopharma Tetraphase Pharmaceuticals (NASDAQ: TTPH) soared nearly 27% today after the company announced positive top-line results for a phase 3 trial evaluating its lead
Here's Why Integra LifeSciences Holdings Corp. Is Sinking Today
Shares of Integra LifeSciences (NASDAQ: IART), a medical device company that focuses on surgical products, fell as much as 11% in early morning trading on Wednesday after the release of second-quarter